GPCR Targeting Technologies: The Next Frontier
Post# of 155203
(Total Views: 423)
Posted On: 07/17/2025 6:24:45 AM
GPCR Targeting Technologies: The Next Frontier in Drug Discovery and Market Consolidation Opportunities
Oncology:
GPCRs regulate tumor growth, metastasis, and immune evasion. Leronlimab (CytoDyn), a CCR5 antagonist, is in Phase II trials for HIV-associated non-alcoholic steatohepatitis (NASH) and solid tumors, while POTELIGEO (Kyowa Kirin) targets CCR4-positive T-cell lymphomas.
and
Market Consolidation: The Players to Watch
The sector is consolidating around companies with deep pipelines, proprietary technologies, and strategic alliances:
CytoDyn (CYDY):
Its lead asset, Leronlimab, targets CCR5—a receptor implicated in HIV, NASH, and cancer. A successful Phase III trial in NASH could propel CYDY's valuation, though its stock has been volatile due to regulatory hurdles.
https://www.ainvest.com/news/gpcr-targeting-t...ties-2507/
(14)
(0)